Cytovac stumbles in key indication and goes on the hunt for capital

Biotech company Cytovac will try to raise DKK 15 million (USD 2.2 million) to keep the company going, after the firm's key asset Alecsat has failed a phase II study as a treatment for brain cancer.

Acting CEO Lone Dahl Andersen did not wish to comment on the study results or the upcoming capital hunt. Photo: Cytovac/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles